https://www.mdedge.com/edermatologynews/article/132494/atopic-dermatitis/nemolizumab-improves-pruritus-atopic-dermatitis
Nemolizumab improves pruritus in atopic dermatitis | MDedge
atopic dermatitisnemolizumabimprovespruritus
https://www.nice.org.uk/guidance/ta1077
Overview | Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and...
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over
https://www.businesswire.com/news/home/20260328320362/en/AAD-2026-Late-Breaking-Nemolizumab-Data-Demonstrate-Clinically-Meaningful-Benefits-for-Children-Aged-2-to-11-With-Moderate-to-Severe-Atopic-Dermatitis
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children...
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with modera...
aad 2026
https://www.marketscreener.com/news/galderma-nemolizumab-data-demonstrate-benefits-for-children-moderate-to-severe-atopic-dermatitis-ce7e51d8de80f727
Galderma - Nemolizumab data demonstrate benefits for children moderate-to-severe atopic dermatitis...
Mar 30, 2026 - Galderma Group AG said on Saturday: AAD 2026: Late-breaking nemolizumab data demonstrate clinically meaningful benefits for children aged 2 to 11 with...
for children